Premium
Basic fibroblast growth factor reduces scar formation in acute incisional wounds
Author(s) -
Ono Ichiro,
Akasaka Yoshikiyo,
Kikuchi Risa,
Sakemoto Akiko,
Kamiya Takafumi,
Yamashita Toshiharu,
Jimbow Kowichi
Publication year - 2007
Publication title -
wound repair and regeneration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.847
H-Index - 109
eISSN - 1524-475X
pISSN - 1067-1927
DOI - 10.1111/j.1524-475x.2007.00293.x
Subject(s) - medicine , basic fibroblast growth factor , scars , hypertrophic scar , dermis , surgery , wound healing , hypertrophic scars , growth factor , pathology , receptor
In order to identify a means to reduce scar formation of the skin after incision, this study examined the effect of local administration of basic fibroblast growth factor (bFGF) in humans. bFGF was administered to a sutured wound immediately after an operation. The drug was injected once into the dermis of the margins of wounds using a 27G needle or rinsing after performing dermostitches. The lengths of the treated wounds varied from 1 to 32 cm, and the subjects were 2–86 years old. Sutured wounds after excision of skin tumors from the face, trunk, and limbs and sutured wounds such as those at the donor sites of full‐thickness skin grafts were treated with low‐dose bFGF injections (0.1 μg/cm wound; Group 2), high‐dose bFGF injections (1 μg/cm wound; Group 3), and rinsed with high‐dose bFGF (1 μg/cm wound; Group 4). No patient treated with bFGF had hypertrophic scars, while some patients had hypertrophic or very wide scars in the control group (Group 1), and the ratios of minimum scarring of Group 2 ( p <0.001), Group 3 ( p <0.0001), and Group 4 ( p <0.0001) were statistically significantly higher than those of Group 1. Postoperative administration of bFGF inhibited hypertrophic scarring and widening of remaining scars without any serious side effects.